BioSpace News Archive

The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™.

Mr. Michael McCune, Nirvana’s Vice President of Operations commented, “This is a major step for the Company, the ability to develop and distribute unique products through a Health Canada licensed facility that has full analytical capabilities will allow Nirvana to offer the highest level of quality assurance.

Increasing prevalence of diabetes and obesity across the globe, rising dependency on insulin therapy, and rapid technological advancements in insulin delivery devices are some key factors expected to drive demand for insulin and fuel market revenue growth over the forecast period.

Major factors driving market revenue growth are increasing in awareness regarding chronic diseases and rising availability of nanoemulsion treatments.

According to the latest report by Reports and Data, the global metabolomics market size was USD 1.88 Billion in 2020 and is expected to reach USD 5.10 Billion in 2028 and register a revenue CAGR of 13.2% during the forecast period, 2021-2028.

Increasing prevalence of chronic illnesses and various types of cancers is compelling various major pharmaceutical companies for developing and launching new medicines and drugs. These drugs undergo clinical trials for evaluating drug efficacy and safety. Pharmacovigilance, also known as drug safety, is a process related to collection, detection, monitoring, and prevention of adverse reactions of drugs and medicines, and plays a vital role in identifying adverse drug effects.

Key factors driving global market revenue growth are technological advancements in molecular genetics and rising demand for biologics. In addition, increasing prevalence of various chronic diseases such as diabetes, multiple sclerosis, and cancer is expected to boost market revenue growth over the forecast period.

Avanos Medical, Inc. announced that Michael Greiner, senior vice president and chief financial officer, will present and participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Monday, May 23 at approximately 1:15 p.m., ET.

In a new cell model study, the patented LCS101 formula eliminated up to 90% of cancer cells within 72 hours.

POXEL SA (Euronext: POXEL - FR0012432516), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL065 and PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy (ALD).